



Supplemental Figure S1. Comparison of ex vivo sensitivity to venetoclax combinations with respect to their constituent single-agent drugs.

For each of 26 different venetoclax partner drug combinations screened, distributions of matched ex vivo sensitivity (as measured by the area under the dose response curve (AUC)) among primary AML patient samples for each combination and its single agents is shown. Partner drug distributions are shown in teal color and combinations in orange. Boxplots indicate median, interquartile range, and range. Differences in sample numbers evaluated for each combination are due to different combinations being added to ex vivo screening panels over time.